NYSE:TAK (Japan) Also trade in: Germany Japan Mexico Switzerland UK

Takeda Pharmaceutical Co Ltd

$ 17.84 -0.15 (-0.83%)
On watch
Volume: 324,268 Avg Vol (1m): 2,066,193
Market Cap $: 55.91 Bil Enterprise Value $: 102.60 Bil
P/E (TTM): 22.53 P/B: 1.18
Earnings Power Value -8.86
Net Current Asset Value -16.7
Tangible Book -11.39
Projected FCF 15.35
Median P/S Value 22.23
Graham Number 0
Peter Lynch Value 7.5
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4.4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.13
Cash-To-Debt range over the past 10 years
Min: 0.13, Med: 42.61, Max: 501.34
Current: 0.13
0.13
501.34
Equity-to-Asset 0.37
Equity-to-Asset range over the past 10 years
Min: 0.37, Med: 0.72, Max: 0.8
Current: 0.37
0.37
0.8
Debt-to-Equity 1.12
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.01, Max: 1.12
Current: 1.12
0
1.12
Debt-to-EBITDA 12.63
Debt-to-EBITDA range over the past 10 years
Min: 0.04, Med: 2.16, Max: 12.76
Current: 12.63
0.04
12.76
Interest Coverage 2.33
Interest Coverage range over the past 10 years
Min: 2.33, Med: 6.7, Max: 294.06
Current: 2.33
2.33
294.06
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.82
DISTRESS
GREY
SAFE
Beneish M-Score -1.88
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 5.56%
WACC 3.29%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 9.77
Operating Margin range over the past 10 years
Min: -7.27, Med: 9.39, Max: 28.66
Current: 9.77
-7.27
28.66
Net Margin % 5.20
Net Margin range over the past 10 years
Min: -8.2, Med: 7.44, Max: 20.31
Current: 5.2
-8.2
20.31
ROE % 4.07
ROE range over the past 10 years
Min: -6.33, Med: 5.95, Max: 14.41
Current: 4.07
-6.33
14.41
ROA % 1.70
ROA range over the past 10 years
Min: -3.29, Med: 3.35, Max: 10.67
Current: 1.7
-3.29
10.67
ROC (Joel Greenblatt) % 20.41
ROC (Joel Greenblatt) range over the past 10 years
Min: -19.36, Med: 28.34, Max: 76.57
Current: 20.41
-19.36
76.57
3-Year Total Revenue Growth Rate 5.10
3-Year Revenue Growth Rate range over the past 10 years
Min: -1.8, Med: 4.2, Max: 11.6
Current: -1.8
-1.8
11.6
3-Year Total EBITDA Growth Rate 8.80
3-Year EBITDA Growth Rate range over the past 10 years
Min: -28.3, Med: 1.3, Max: 42.7
Current: 1.6
-28.3
42.7
3-Year EPS w/o NRI Growth Rate 3.50
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -0.8, Max: 31.4
Current: 3.5
0
31.4

» TAK's 30-Y Financials

Financials (Next Earnings Date: 2019-07-31)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:TAK

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers    NAICS : 325412    SIC : 2834
Compare NYSE:AGN NYSE:ZTS XTER:MRK SHSE:600276 TSE:4507 TSE:4523 TSX:WEED NSE:SUNPHARMA SZSE:000538 NYSE:ELAN XPAR:IPN SZSE:300122 XTAE:TEVA NAS:MYL SHSE:600332 XSWX:VIFN SHSE:600196 TSX:BHC NYSE:CTLT TSX:ACB
Traded in other countries TKD.Germany 4502.Japan 4502.Switzerland 0RN3.UK
Address 4-1-1 Doshomachi, Chuo-ku, Osaka, JPN, 540-8645
Takeda is Japan's largest pharmaceutical company, with annual revenue around $16 billion and a focus on four therapeutic areas: oncology, gastroenterology, vaccines, and neurology. Roughly 40% of its revenue comes from Japan. The Millennium acquisition (2008) brought rights to Velcade, Ninlaro, and Entyvio. The Nycomed acquisition (2011) expanded Takeda's exposure to Europe and emerging markets. Other notable products include Azilva (blood pressure), leuprorelin (prostate cancer), and Trintellix (depression).

Ratios

Current vs industry vs history
PE Ratio (TTM) 22.53
PE Ratio range over the past 10 years
Min: 6.78, Med: 24.64, Max: 90.74
Current: 22.53
6.78
90.74
Forward PE Ratio 119.05
N/A
PE Ratio without NRI 22.53
PE without NRI range over the past 10 years
Min: 6.78, Med: 24.64, Max: 90.74
Current: 22.53
6.78
90.74
Price-to-Owner-Earnings 17.11
Price-to-Owner-Earnings range over the past 10 years
Min: 10.56, Med: 16.59, Max: 581.37
Current: 17.11
10.56
581.37
PB Ratio 1.18
PB Ratio range over the past 10 years
Min: 1.11, Med: 1.59, Max: 2.46
Current: 1.18
1.11
2.46
PS Ratio 1.79
PS Ratio range over the past 10 years
Min: 1.64, Med: 2.19, Max: 12.29
Current: 1.79
1.64
12.29
Price-to-Free-Cash-Flow 19.44
Price-to-Free-Cash-Flow range over the past 10 years
Min: 10.03, Med: 20.82, Max: 96.74
Current: 19.44
10.03
96.74
Price-to-Operating-Cash-Flow 11.36
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 7.75, Med: 15.44, Max: 179.76
Current: 11.36
7.75
179.76
EV-to-EBIT 60.65
EV-to-EBIT range over the past 10 years
Min: -47.1, Med: 18.7, Max: 67.6
Current: 60.65
-47.1
67.6
EV-to-EBITDA 24.34
EV-to-EBITDA range over the past 10 years
Min: 3.3, Med: 11.4, Max: 59.1
Current: 24.34
3.3
59.1
EV-to-Revenue 5.28
EV-to-Revenue range over the past 10 years
Min: 1.4, Med: 2.3, Max: 12.3
Current: 5.28
1.4
12.3
PEG Ratio 2.80
PEG Ratio range over the past 10 years
Min: 1.35, Med: 2.86, Max: 319
Current: 2.8
1.35
319
Shiller PE Ratio 21.27
Shiller PE Ratio range over the past 10 years
Min: 8.76, Med: 19.49, Max: 25.75
Current: 21.27
8.76
25.75
Current Ratio 1.21
Current Ratio range over the past 10 years
Min: 0.92, Med: 3.3, Max: 5.39
Current: 1.21
0.92
5.39
Quick Ratio 0.82
Quick Ratio range over the past 10 years
Min: 0.76, Med: 3, Max: 5.13
Current: 0.82
0.76
5.13
Days Inventory 207.80
Days Inventory range over the past 10 years
Min: 140.34, Med: 169.88, Max: 331.89
Current: 207.8
140.34
331.89
Days Sales Outstanding 129.12
Days Sales Outstanding range over the past 10 years
Min: 72.18, Med: 87.9, Max: 129.12
Current: 129.12
72.18
129.12
Days Payable 181.14
Days Payable range over the past 10 years
Min: 92.31, Med: 143.03, Max: 250.84
Current: 181.14
92.31
250.84

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 4.54
Trailing Dividend Yield range over the past 10 years
Min: 2.71, Med: 3.99, Max: 6.48
Current: 4.54
2.71
6.48
Dividend Payout Ratio 1.62
Dividend Payout Ratio range over the past 10 years
Min: 0.48, Med: 1.15, Max: 1.77
Current: 1.62
0.48
1.77
Forward Dividend Yield % 4.64
N/A
Yield-on-Cost (5-Year) % 4.51
Yield-on-Cost (5y) range over the past 10 years
Min: 2.71, Med: 3.99, Max: 6.48
Current: 4.51
2.71
6.48
3-Year Share Buyback Rate -7.30
3-Year Share Buyback Rate range over the past 10 years
Min: -7.3, Med: 0, Max: 3.9
Current: -7.3
-7.3
3.9

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.17
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.14, Med: 1.6, Max: 2.13
Current: 1.17
1.14
2.13
Price-to-Median-PS-Value 0.80
Price-to-Median-PS-Value range over the past 10 years
Min: 0.8, Med: 1.04, Max: 1.21
Current: 0.8
0.8
1.21
Price-to-Peter-Lynch-Fair-Value 2.39
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.93, Med: 1.57, Max: 3.61
Current: 2.39
0.93
3.61
Earnings Yield (Joel Greenblatt) % 1.65
Earnings Yield (Greenblatt) range over the past 10 years
Min: -3.4, Med: 4.9, Max: 23.8
Current: 1.65
-3.4
23.8
Forward Rate of Return (Yacktman) % 13.52
Forward Rate of Return range over the past 10 years
Min: -18.8, Med: -5, Max: 17.3
Current: 13.52
-18.8
17.3

More Statistics

Revenue (TTM) (Mil) $ 18,833.9
EPS (TTM) $ 0.78
Beta 0.94
Volatility % 29.3
52-Week Range $ 15.5 - 21.95
Shares Outstanding (Mil) 1,578.73

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y